A new academic paper concludes that many women don't think of starting businesses because they lack access to the role models, mentors and networks that could help them become entrepreneurs. "Women are just outside of those established networks, and if you're outside the networks, you don't get the knowledge, you don't get the opportunities, you don't get the contacts and you don't get the funding," said the paper's co-author Susan Coleman, a business professor at the University of Hartford.
The American Medical Association elected oncologist Barbara McAneny president-elect, and she will become the fourth female AMA president when she begins her term next July. McAneny served as chairwoman of the AMA's board from 2015 to 2016, served on the American Society of Clinical Oncology's board and was president of the New Mexico Medical Society, the Greater Albuquerque Medical Association and the American College of Physicians' New Mexico chapter.
Former Forum Pharmaceuticals Vice President Karen Brennan was appointed chief operating officer at Checkmate Pharmaceuticals, which recently raised $27 million in a Series B financing round. The company's lead drug candidate is an oligonucleotide embedded in a viruslike particle, which is being tested in combination with Merck's checkpoint inhibitor Keytruda.
Psychologist Patricia Devine led a study that sought to determine whether NIH grant application reviewers are biased against nonwhite or female applicants by substituting fictitious, stereotypical names on past applications and analyzing how the proposals are scored by new reviewers. She hopes to begin analyzing the data in July.
Julie Legault, Amino Labs' founder, creative director and CEO, learned how to engineer a bacteria into a new compound and how to apply synthetic biology to develop specific compounds, such as scents, during a workshop at the MIT Media Lab that led her to establish the biotechnology firm. "The hope is that as more people create companies and create similar products and as accessible bio grows, there will be products that will help you through the whole trajectory from the first experiment to creating something," Legault said.
While synthetic biology has since been used in industrial processes such as agriculture, the technology is increasingly being used in industries that do not require biological processes, including construction materials, mining and adhesives, writes Gigi Kwik Gronvall, a senior associate of the Johns Hopkins Center for Health Security. However, synthetic biology still faces several barriers to its adoption, such as "a lack of accurate and detailed economic data on the role of bio-based production in the economy" and "a weak governance framework," Gronvall writes.
A UK study in the American Journal of Obstetrics & Gynecology found women who used combined oral contraceptives had lower risks of colorectal cancer, ovarian cancer, endometrial cancer, and lymphatic and hematopoietic cancer. The findings, based on 46,022 women enrolled in the Royal College of General Practitioner's Oral Contraception Study, showed these protective benefits against cancer persisted at least 30 years following contraceptive use cessation.
A list known as the Foundation 500 features the accomplishments of 500 women entrepreneurs in emerging markets where women are often denied education and financing. Humanitarian agency CARE and the nonprofit H&M Foundation back the initiative, which seeks to break down barriers to women's entrepreneurship.
Applying online can often be a poor way of getting a company's attention, but job seekers can improve their chances by sending a personalized email to a hiring manager, say members of the Young Entrepreneur Council. It's also possible to connect with a hiring manager or employee of a company you're interested in via LinkedIn.
Eleven veterinary clinics across the Canadian province of Prince Edward Island are participating in a study led by Mount Allison University master's degree student Alexandra Foley-Eby to collect and test ticks for Lyme disease. Foley-Eby is also testing healthy dogs' blood and hopes to use the data to predict the incidence of Lyme disease in humans.
Please join us for our signature annual WIB Plenary Event on Monday, June 19, at the beautiful Manchester Grand Hyatt. The evening will open with a presentation by keynote speaker Carol Gallagher, Pharm.D, partner of New Enterprise Associates. We will then move into our Pitch Challenge, where women leaders in the life sciences will deliver pitches and receive valuable feedback from top female investors on presentation and delivery.
As with all WIB events, our Plenary Event encompasses an inviting and fun environment for networking as it brings together people from all corners of the life sciences industry, and spawns new career and business opportunities. This event is not to be missed! Online registration ends today!